Back to top

crispr: Archive

Sundeep Ganoria

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

REGNNegative Net Change BEAMNegative Net Change NTLANegative Net Change

Zacks Equity Research

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.

ALKSNegative Net Change VRTXPositive Net Change CRMDNegative Net Change CRSPNegative Net Change

Sundeep Ganoria

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

VRTXPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change